Introduction {#sec1-2055217319892291}
============

Higher serum concentrations of 25-hydroxyvitamin D (25(OH)D) have repeatedly been associated with a decreased risk of multiple sclerosis (MS) development in nested case--control studies^[@bibr1-2055217319892291][@bibr2-2055217319892291]--[@bibr3-2055217319892291]^ with one study showing a larger effect before 20 years of age.^[@bibr1-2055217319892291]^ Additional support for a causal role of vitamin D in MS aetiopathogenesis comes from Mendelian randomisation studies^[@bibr4-2055217319892291],[@bibr5-2055217319892291]^ but this subject remains controversial.^[@bibr6-2055217319892291]^

In this study we aimed to test the hypothesis that high 25(OH)D concentrations reduce the risk of developing MS, with a more pronounced effect among young individuals, by comparing blood samples from healthy controls to samples from individuals who later developed relapsing--remitting multiple sclerosis (RRMS). To achieve these goals, we accessed six Swedish biobanks specifically chosen because they include plasma or serum drawn at a young age.

Materials and methods {#sec2-2055217319892291}
=====================

Case ascertainment {#sec3-2055217319892291}
------------------

In this nested case--control study we accessed five Swedish microbiological biobanks associated with university hospitals in Umeå, Örebro, Göteborg, Skåne and Linköping and one biobank from the Public Health Agency of Sweden (PHAS), to obtain serum or plasma from a total of 670 individuals who later developed RRMS and 670 controls matched for biobank and sex, and with decreasing priority for date of sampling and age. These biobanks contain remainders from serological analysis in routine clinical practice. Cases were identified either through crosslinking with the Swedish MS registry ([www.neuroreg.se](http://www.neuroreg.se)) or a local MS/possible MS database, and a total of 665 complete sets of cases and controls were included in the final analysis (see Supplementary Figure 1). All samples from MS patients were collected 8 years prior to symptom onset (in median) and all participants were below 40 years of age at the time of sampling. The absolute mean difference between cases and controls was 6 days for the date of sampling and 152 days for the age at sampling.

Laboratory analysis {#sec4-2055217319892291}
-------------------

The concentration of 25(OH)D~3~ was analysed using liquid chromatography tandem mass spectrometry (LC-MS/MS) as described previously.^[@bibr7-2055217319892291]^ Samples for matched cases and controls were analysed immediately after each other and in random order, and technicians were blinded to case--control status.

Statistical analysis {#sec5-2055217319892291}
--------------------

We modelled 25(OH)D~3~ levels as quintiles, derived from the distribution among controls, separately for each biobank as the levels differed significantly between them (Kruskal--Wallis test *P* ≤ 0.001). These quintile assignments were used in a pooled analysis that included all individuals. The Mann--Whitney U-test was used to test differences between groups, odds ratios (ORs) and *P* for trend over quintiles were calculated using conditional logistic regression. Age was stratified into three groups based on the age at sample draw, less than 20, 20--29 and 30--39 years of age. If a case--control set was on different sides of an age cut-off they were assigned to either the youngest or oldest group containing either a case or control, in order to increase power in the smaller groups. IBM SPSS statistics version 23 (IBM Corporation, New York, NY, USA) was used for statistical analysis.

Ethical considerations {#sec6-2055217319892291}
----------------------

This study was approved by a local regional ethical review board in Umeå (2011-198-31M). No written informed consent was required for participation.

Results {#sec7-2055217319892291}
=======

Median 25(OH)D~3~ did not differ between cases and controls ([Table 1](#table1-2055217319892291){ref-type="table"}). Being in the top 25(OH)D~3~ quintile was significantly associated with a decreased risk of MS in the total cohort (OR 0.68, 95% confidence interval (CI) 0.50--0.93) ([Table 2](#table2-2055217319892291){ref-type="table"}). A sensitivity analysis excluding the PHAS biobank, which had higher levels compared to the others, yielded an OR of 0.69 (95% CI 0.49--0.97) when using the median cut-off for the remaining biobanks (72 nmol/L). Subgroup analyses in different age strata were not significant and we found no trend over 25(OH)D~3~ quintiles.

###### 

Characteristics of cases and controls.

![](10.1177_2055217319892291-table1)

                                                  *n*   Cases         *n*    Controls      *P* value
  ----------------------------------------------- ----- ------------- ------ ------------- -----------
  Sex (M/F)                                       665   16.2/83.8%    665    16.2/83.8%    
  Age at sampling, years                          665   25 (21--29)   665    25 (21--29)   
  Age at disease onset, years                     665   33 (28--40)   n.a.                 
  Time from sampling until disease onset, years   665   8 (4--13)     n.a.                 
  Biobank -- latitude                                                                      
   Umeå -- 63°N                                   102   15.3%         102    15.3%         
    Vitamin D3                                          47 (37--61)          53 (39--68)   0.07
    Samples collected between, years                    1976--2007           1976--2007    
   PHAS -- n.a.                                   137   20.6%         137    20.6%         
    Vitamin D3                                          59 (43--75)          56 (39--77)   0.64
    Samples collected between, years                    1972--2001           1972--2001    
   Örebro -- 59°N                                 29    4.3%          29     4.3%          
    Vitamin D3                                          52 (41--63)          50 (36--70)   0.96
    Samples collected between, years                    1994--2008           1994--2008    
   Göteborg -- 57°N                               47    7.1%          47     7.1%          
    Vitamin D3                                          56 (41--65)          55 (44--67)   0.97
    Samples collected between, years                    1995--2009           1995--2009    
   Skåne -- 55°N                                  311   46.8%         311    46.8%         
    Vitamin D3                                          52 (41--68)          52 (40--70)   0.93
    Samples collected between, years                    1977--2007           1977--2007    
   Linköping -- 58°N                              39    5.9%          39     5.9%          
    Vitamin D3                                          43 (30--57)          51 (32--61)   0.33
    Samples collected between, years                    1993--2009           1993--2009    
  All subjects                                    665                 665                  
   Vitamin D3                                           53 (40--67)          53 (39--70)   0.50
  Age group \<20 years                            142                 142                  
   Vitamin D3                                           49 (38--64)          51 (39--67)   0.47
  Age group 20--29 years                          374                 374                  
   Vitamin D3                                           53 (41--67)          53 (39--71)   0.73
  Age group 30--39 years                          149                 149                  
   Vitamin D3                                           55 (41--72)          56 (42--73)   0.83

PHAS: Public Health Agency of Sweden.

Median (25th--75th percentiles) for continuous variables and percentages for proportions.

Vitamin D concentrations expressed as nmol/L.

###### 

Associations of vitamin D~3~ concentration and MS stratified by biobank and age.

![](10.1177_2055217319892291-table2)

                                                                Vitamin D categories   Cut-off nmol/L   Number of (%)   OR           95% CI   
  ------------------------------------------------------------- ---------------------- ---------------- --------------- ------------ -------- ------------
  Biobank                                                                                                                                     
   Umeå                                                         Quintile 1--4          38, 48, 59       90 (88.2)       81 (79.4)    ref      
                                                                Quintile 5             ≥73              12 (11.8)       21 (20.6)    0.47     0.20--1.1
   PHAS                                                         Quintile 1--4          37, 50, 63       114 (83.2)      109 (79.6)   ref      
                                                                Quintile 5             ≥82              23 (16.8)       28 (20.4)    0.75     0.38--1.5
   Örebro                                                       Quintile 1--4          35, 48, 60       26 (89.7)       23 (79.3)    ref      
                                                                Quintile 5             ≥72              3 (10.3)        6 (20.7)     0.40     0.08--2.1
   Göteborg                                                     Quintile 1--4          41, 50, 59       41 (87.2)       37 (78.7)    ref      
                                                                Quintile 5             ≥71              6 (12.8)        10 (21.3)    0.43     0.11--1.7
   Skåne                                                        Quintile 1--4          38, 47, 58       252 (81.0)      248 (79.7)   ref      
                                                                Quintile 5             ≥73              59 (19.0)       63 (20.3)    0.90     0.58--1.4
   Linköping                                                    Quintile 1--4          27, 42, 55       37 (94.9)       31 (79.5)    ref      
                                                                Quintile 5             ≥70              2 (5.1)         8 (20.5)     0.25     0.05--1.2
   All                                                          Quintile 1--4                           560 (84.2)      529 (79.5)   ref      
                                                                Quintile 5                              105 (15.8)      136 (20.5)   0.68     0.50--0.93
   All^[a](#table-fn5-2055217319892291){ref-type="table-fn"}^   Quintile 1                              134 (20.1)      133 (20.0)   ref      
                                                                Quintile 2                              142 (21.4)      133 (20.0)   1.1      0.77--1.5
                                                                Quintile 3                              131 (19.7)      130 (19.5)   0.99     0.71--1.4
                                                                Quintile 4                              153 (23.0)      133 (20.0)   1.1      0.78--1.6
                                                                Quintile 5                              105 (15.8)      136 (20.5)   0.72     0.49--1.1
  Age group                                                                                                                                   
   \<20                                                         Quintile 1--4                           126 (88.7)      118 (83.1)   ref      
                                                                Quintile 5                              16 (11.3)       24 (16.9)    0.60     0.29--1.2
   20--29                                                       Quintile 1--4                           313 (83.7)      297 (79.4)   ref      
                                                                Quintile 5                              61 (16.3)       77 (20.6)    0.70     0.46--1.1
   30--39                                                       Quintile 1--4                           121 (81.2)      114 (76.5)   ref      
                                                                Quintile 5                              28 (18.8)       35 (23.5)    0.72     0.39--1.3

MS: multiple sclerosis; OR: odds ratio; CI: confidence interval; PHAS: Public Health Agency of Sweden.

^a^In the total cohort, *P* for trend over quintiles was 0.24.

Discussion {#sec8-2055217319892291}
==========

Although cases and controls did not significantly differ in median levels of 25(OH)D and there was no significant trend over quintiles, we did find a decreased MS risk among individuals with concentrations in the top quintile. These findings suggest that there may exist a threshold located within the higher range of 25(OH)D levels (cut-off 70--82 nmol/L in the six biobanks) above which the effect of 25(OH)D modulates MS risk. This is in line with the findings of one earlier study using 75 nmol/L as a cut-off.^[@bibr2-2055217319892291]^ Data from the currently largest pre-symptomatic study, performed in a Finnish maternity cohort,^[@bibr3-2055217319892291]^ seem to indicate that seasonally corrected levels above 50 nmol/L are protective when compared to less than 30 nmol/L. In that study, 6% of cases and 7.5% of controls were above 50 nmol/L, compared to 54.6% and 56.1% in our study. Although we found higher vitamin D levels, they are in line with previously published population-based studies in our region.^[@bibr8-2055217319892291]^ Differences in methodology, including 25(OH)D assay and the use of seasonal correction of multiple samples from each individual in the Finnish study, may explain some of the differences in absolute 25(OH)D and a direct comparison between the studies may therefore be inappropriate.^[@bibr9-2055217319892291]^

A strength of our study is the relatively large number of individuals below 20 years of age, enabling comparisons of different age strata. These analyses did not yield any significant findings, however, but the effect sizes converge with earlier studies.^[@bibr1-2055217319892291],[@bibr2-2055217319892291]^ Furthermore, this is to our knowledge the first study applying the gold standard method LC-MS/MS.

The main limitation in our study is that the samples came from six unique biobanks, with different pre-analytical procedures and geographically distinct catchment areas, both of which may influence the results as well as provide a geographical explanation of why serum concentrations of vitamin D differed between biobanks. To minimise this, we matched cases and controls from the same biobank and defined quintiles separately for each biobank. Pooling of site-specific quintiles has been used previously^[@bibr10-2055217319892291]^ and enabled analysis of the total cohort by applying a similar relative cut-off (i.e. top quintile), despite the biobanks representing a heterogenous material. Also, we did not have access to data on race/ethnicity and the results may therefore not be generalisable to other populations. In addition, the retrospective compilation of data may have implicated other biases affecting the results that we have not considered.

In conclusion, our results further support the hypothesis that relatively higher 25(OH)D concentrations may protect against the development of MS but not that the effect is stronger among young individuals.
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Click here for additional data file.
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